Israel's Medical Cannabis Market Size (2026)

Israel is one of the most consequential cannabis markets in the world relative to its population — but "size" needs unpacking here, because published estimates disagree by a factor of two and the legal market is only a sliver of actual consumption. This guide lays out the numbers, shows how to sanity-check them, and explains what caps them.

This guide is informational and is not investment or medical advice. Market figures are estimates and vary by source and by level of trade.

The headline figures — and why they conflict

There is no official published revenue figure for Israel's medical cannabis market, so every number in circulation is a modelled estimate. The common ones:

• Roughly US$372 million for 2025 (Statista).
• A materially lower base of about US$159 million, forecast to reach roughly US$327 million by 2025, in Dun & Bradstreet's sector analysis (Dun & Bradstreet Israel).
• A historical anchor: Israeli medical cannabis sales in 2019 came to about NIS 300 million at consumer prices, including pharmacy and distributor margins and VAT (Dun & Bradstreet Israel).

The spread is not sloppiness. Estimates differ mainly on which level of trade they measure — producer revenue, wholesale, or consumer prices including VAT and pharmacy margin can differ by 50% or more on identical volumes. Treat any single figure as an order of magnitude: a few hundred million dollars, not a billion, and not fifty million.

A bottom-up check on the volume

Because the revenue estimates are shaky, the more reliable way to size this market is by grams, working from the patient base.

Israel's licensed patient population reached an all-time high of about 143,900 in May 2026 (see our patient-numbers guide), and Dun & Bradstreet's analysis finds that about 62% of patients consume more than 30 grams a month (Dun & Bradstreet Israel).

Run that arithmetic as a cross-check, with the assumptions stated openly:

• At a flat 30 g per patient per month, the market consumes roughly 52 tonnes a year. Because a clear majority consume more than 30 g, treat this as a floor.
• At a plausible average of 45 g per month, it comes to roughly 78 tonnes a year.

That bracket is corroborated independently. Canada shipped about 20 tonnes to Israel in 2024, described as roughly a quarter of total market volume — implying a total near 80 tonnes (GrowerIQ). Two unrelated methods landing in the same 50–80 tonne range is about as much confidence as this market allows.

Apply a pharmacy price in the ballpark of ₪15–25 per gram (legal flower commonly runs around ₪100–350 per 10 g depending on product and outlet) and the implied consumer-level market lands between roughly ₪0.8 billion and ₪2.0 billion — about US$220–540 million at around ₪3.6 to the dollar. The published US$372 million sits comfortably inside that band, which is the main reason to trust the order of magnitude even while distrusting the precision.

The number that really matters: legal versus illicit

The single most important fact about market size in Israel is the gap between legal and illicit consumption. Industry estimates put illicit users in the low millions — around 2.4 million estimated illicit users against roughly 132,800 legal medical patients in 2025 (GrowerIQ). The regulated channel serves well under 10% of actual cannabis consumption in the country.

That gap is the entire long-term growth thesis for licensed operators. The addressable market is not really 143,900 patients; it is the millions of people currently served by the illicit market. Converting even a modest fraction of them would multiply the regulated market several times over — which is also why recreational legalisation is treated as a commercial question, not only a political one.

What the market is made of

Two structural facts shape where the money goes:

• It is overwhelmingly a flower market. Flower-based products accounted for over 94% of medical cannabis usage by 2025, according to a peer-reviewed review of Health Ministry data (Journal of Cannabis Research, 2025). About 87% of patients consume by smoking, and about 88% of licences are for high-THC products (Dun & Bradstreet Israel).
• It is strictly medical. There is no legal recreational market (see is cannabis legal in Israel?), so every shekel of regulated revenue moves through the Health Ministry licence-and-pharmacy system.

The flower concentration is why a regulatory move against smokable formats is a market-size question and not a niche one — a shift away from raw flower would touch over 90% of consumption. The same logic applies to trade: because roughly a third of product is imported, tariff decisions feed straight into prices. See imports and supply and what medical cannabis costs.

What constrains it

Three things cap the legal market in practice:

• Medical-only framework. The ceiling is set by how many people can obtain a licence, not by how many want cannabis.
• Uneven patient growth. The base contracted after the 2024 HMO-led prescribing reform before recovering to its May 2026 high — growth has not been the smooth line the early years suggested.
• Cost. Cannabis sits outside the subsidised health basket, so price deters some patients outright and pushes others toward the illicit channel.

Together these explain why a country with world-leading research and one of the largest per-capita patient populations anywhere still has a legal market measured in hundreds of millions, not billions.

The takeaway

Israel's legal cannabis market is best understood as roughly 50–80 tonnes a year, worth a few hundred million dollars, overwhelmingly flower, and dwarfed by illicit consumption several times its size. The bull case is conversion of that illicit demand; the bear case is that a medical-only framework, renewal friction and price sensitivity keep the regulated market boxed in. Anyone quoting a single precise figure for this market is quoting a model, not a measurement.

For the demand side, see Israel's cannabis patient numbers; for how Israel compares internationally, Israel versus the global market; for the companies dividing this market up, the Companies hub and our company directory; and for the full picture, our Market hub.